Joern Aldag leads the amazing Hookipa Biotech team as Chief Executive Officer. Before joining Hookipa in June 2016, Joern was CEO of NASDAQ-listed uniQure N.V, a company pioneering adeno-associated virus-based gene therapy. Under his leadership from 2009-2015, uniQure received the first-ever approval of a gene therapy product by the European Medicines Agency, built a pipeline of gene therapy products across several disease areas, obtained approximately $200M through its NASDAQ-listing and follow-on, and closed a multi-billion dollar collaboration in cardiovascular gene therapy. Alongside his CEO role at Hookipa, Joern is Chairman of Molecular Partners AG and a Board member of Unum Therapeutics, both of which are developing next-gen immuno-oncology therapies. Joern holds business degrees from the European Business School and Harvard Business School (AMP).